Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

AZD6244 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Study:

A Phase II Evaluation of AZD6244 (NSC #748727, IND #77782) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Rationale:

AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Purpose:

This phase II trial is studying how well AZD6244 works in treating patients with recurrent or persistent endometrial cancer.

Study Status: Suspended

Recruiting:
n/a

Condition Intervention Phase
Endometrial Cancer Drug: selumetinib
Other: laboratory biomarker analysis
Phase 2

Verified by Gynecologic Oncology Group May, 2010

Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT01011933

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Robert L. Coleman, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site